BPC-157 gets plenty of attention for healing and recovery, but promising animal research isn’t proof of human benefit. An FDA evaluation found insufficient evidence of clinical safety information. Save this before believing the hype. #longevity# #geroscience# #peptide#

GLP-1 receptor agonists and BPC-157 may share the peptide conversation, but their evidence is far from equal. Before believing the hype, ask what was actually studied, in whom, and for how long. Which peptide claim should we examine next? #longevity# #geroscience# #peptides#

Peptides are moving towards approval. This is the first domino in a vastly consequential chain of events that ends with $HIMS being worth $2,000 per share intrinsically by 2030. 1/ BPC-157 and other generic peptides get approved. Millions of people try them. They see results. And then they ask the obvious question: what else can I take? 2/ They ask that question on the platform that already serves them. $HIMS is one of the largest D2C healthcare platforms on Earth, with a vertically integrated supply chain. Vertical integration wins on price. Price wins the customer. 3/ Every customer becomes a source of biomarker data. And that data gets deeper and more exhaustive every year: more patients, more panels, more longitudinal measurements, more before-and-after pairs. Every new customer makes the machine smarter. Every improvement in the machine attracts more customers. 4/ Eventually, the dataset becomes so exhaustive that $HIMS AI can design personalised peptides for virtually anyone. The objective: optimal patient outcomes at a fraction of the cost of competing solutions. Healthcare stops being about prescribing the same molecule to millions of people. It becomes about designing the optimal intervention for each individual. 5/ This is the scenario that takes $HIMS to $2,000 in intrinsic value per share by 2030. In everyone's eyes, it becomes the platform that unlocks an entirely new AI scaling law: life extension per token. It turns the pharmaceutical industry upside down. Traditional drug discovery becomes increasingly obsolete as value migrates towards the AI trained on the largest, deepest and highest-quality longitudinal biomarker dataset. The molecule becomes the output. The intelligence that designs it becomes the asset. 6/ This sends everyone into a race to build or access that intelligence. If you don't own the AI, you're increasingly forced to depend on it. As a pharmaceutical supplier, because competitors using it can design better interventions at lower costs. As a customer, because people using it may achieve better health outcomes and ultimately live longer than those who don't. 7/$HIMS becomes the most valuable subscription service on Earth as its AI grows increasingly predictive. Just as operating without $PLTR can create a massive competitive disadvantage, increasingly comparable to operating without electricity, living outside the $HIMS OS could mean losing access to the most consequential value creation machine in healthcare. Except this time, the output isn't just productivity or economic efficiency. It's additional years of human life.

Peptides are moving towards approval. This is the first domino in a vastly consequential chain of events that ends up in $HIMS being worth $2,000 per share intrinsically by the year 2030. 1/ BPC-157 and the other generic peptides get approved. Millions of people try them. They see results. Then they ask the obvious question: what else can I take? 2/ They ask it on the platform that already has them. $HIMS is the largest D2C healthcare platform on Earth, and the only one with a vertically integrated supply chain. Vertical integration wins on price:value. Price:value wins the customer. 3/ Every customer becomes biomarker data. And the biomarker data gets deeper and more exhaustive every year: more patients, more panels, more before-and-after pairs. 4/ Eventually the data is so exhaustive that $HIMS AI can design personalised peptides for anyone. Optimal patient outcomes, at a fraction of the cost of anyone else in the market. 5/ This is the scenario that takes $HIMS to $2,000 intrinsic value by 2030. In everyone’s eyes, it becomes the platform that unlocks the new AI scaling law: life extension per token. It inverts the entire industry on its head: "drug discovery" gets immediately deprecated and all value accrues to the single AI trained with the most and highest quality biomarker data. 6/ This sends everyone on a race to space: if you don't own this AI, you're forced to succumb to it both as a pharma supplier and as a customer, because not using this AI means others beat you in selling drugs and you just don't live as long as customer, respectively. 7/ It becomes the most valuable subscription service on Earth as the AI gets increasingly predictive. Just like not running $PLTR today is a massive disadvantage, increasingly comparable to not using electricity, not running on the $HIMS OS means you don't have access to the core value creation machine that literally allows anyone in the industry to stay alive.

Today, for the first time, an FDA advisory panel voted to open a legal path for BPC-157 — the most sought-after peptide in the world. That's genuinely a milestone. And it's worth understanding exactly what just happened. The panel voted 8-6 to recommend adding BPC-157 to the list of substances licensed compounding pharmacies can prepare under a real prescription. FDA staff had recommended against it. The panel went the other way. Here's why I think that matters, even as a cautious physician. Right now, millions of people are already taking this. They're buying research-grade powder from anonymous overseas sellers, mixing it on a kitchen counter, and injecting it. Over 40% of gray-market samples fail purity testing. No dosing standards. No sterility guarantee. No adverse-event reporting. No physician watching. A vote like today's is the first real step toward moving all of that into daylight — into licensed pharmacies, with quality control, physician oversight, and traceable safety data. That's a genuine win for patient safety, regardless of what you believe about the molecule. And the underlying science is legitimately exciting. BPC-157 is a synthetic peptide modeled on a protective protein found in human gastric juice. Hundreds of animal studies show accelerated tendon and ligament healing, gut protection, anti-inflammatory effects, and angiogenesis — the growth of new blood vessels. The preclinical signal is strong enough that serious researchers keep coming back to it. That's not nothing. That's why the demand exists in the first place. Now the sober part, because you deserve both halves. The published human evidence is still remarkably thin — roughly 30 subjects in the strongest studies, with the longest treatment lasting about two weeks. And the routes actually studied barely overlap with how people use it today. There are no completed randomized controlled trials for the popular uses. Also worth knowing: today's vote is not FDA approval. It's advisory and non-binding. Formal rulemaking takes 12 to 24 months. Nothing changed legally today. My one clinical caution, and it comes from my own field: the same angiogenesis that may heal a tendon is a signal that says grow. Nobody has studied that over years, and nobody has studied it in cancer survivors. Worth a real conversation with your doctor before you assume it's harmless. But here's the encouraging part. A Phase 2 hamstring trial is already underway. A regulated pathway means better product, real prescriptions, and — crucially — actual data collection instead of anecdotes. This is how a gray market becomes medicine: oversight first, then evidence, then answers. Today was a step in that direction. Now let's get the trials done and find out what this thing can really do.

So the "Peptide Party" has been cancelled after Karanataka State Food and Drug Administration officials took note and reached out to the health and science illiterate organizers. Instead of proving their point and why this party was indeed essential, they just immediately decided to cancel it. If there was any real evidence to the claims they made or for what they were doing, or planned to do, they wouldn't have chickened out. This just goes to show what a shitshow wellness industry really is because any tom, dick and harry can take a product studied in rats and just run it through a party on magical thinking. Independent laboratory testing of underground (like this party and similar party) or online-purchased peptides (such as those marketed for weight loss, or muscle growth like BPC-157 and TB-500) shows actual active ingredient concentrations range wildly from 0% (empty vials) to 190% of the labeled claims. This has led to organ injury, including liver failure. New testing of black market peptides reveals dangerous dosing levels Doctors fear possible contaminated counterfeit peptide batch after seventh case of acute liver damage When doctors like myself advice people to stay away from rubbish like peptides that endanger public, it is not some conspiracy theory. It means public health advisory. But some of the techbros think these peptides are going to put us out of "business" and cure "aging". If there was a peptide for the 'braindead activity' like the promoters of this peptide party have, I'm all for it. So stop with this bullshit before you get killed, or kill someone. Focus on building things that you have some expertise on.